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The fungal part of the pulmonary microbiome (mycobiome) is understudied. We report the
composition of the oral and pulmonary mycobiome in participants with COPD compared to
controls in a large-scale single-centre bronchoscopy study (MicroCOPD).
Methods
Oral wash and bronchoalveolar lavage (BAL) was collected from 93 participants with COPD
and 100 controls. Fungal DNA was extracted before sequencing of the internal transcribed
spacer 1 (ITS1) region of the fungal ribosomal RNA gene cluster. Taxonomic barplots were
generated, and we compared taxonomic composition, Shannon index, and beta diversity
between study groups, and by use of inhaled steroids.
Results
The oral and pulmonary mycobiomes from controls and participants with COPD were domi-
nated by Candida, and there were more Candida in oral samples compared to BAL for both
study groups. Malassezia and Sarocladium were also frequently found in pulmonary sam-
ples. No consistent differences were found between study groups in terms of differential
abundance/distribution. Alpha and beta diversity did not differ between study groups in pul-
monary samples, but beta diversity varied with sample type. The mycobiomes did not seem
to be affected by use of inhaled steroids.
Conclusion
Oral and pulmonary samples differed in taxonomic composition and diversity, possibly indi-
cating the existence of a pulmonary mycobiome.
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Introduction
Fungi are ubiquitous, and are found in indoor and outdoor environments [1]. Due to its direct
communication with surrounding air, the respiratory tract is constantly exposed to fungal
spores through inhalation [2]. Healthy airways possess effective removal of such spores
through mucociliary clearance and phagocytosis. In contrast, impaired defence mechanisms,
use of immunosuppressant, and frequent use of antibiotics probably predispose for increased
fungal growth [2], and all factors are quite frequent in chronic obstructive pulmonary disease
(COPD).
The fungal part of the microbiome, the mycobiome, of the lungs is understudied [3], and
only three studies have used next generation sequencing to study the mycobiome of the respi-
ratory tract in COPD particularly [4–6]. Notably, participants in Cui et al.´s study were also
HIV infected, and only ten had COPD [4]. The study by Su et al. [5] and Tiew et al. [6] used
sputum samples, which are vulnerable to contamination from the high-biomass oral cavity. By
contrast, mycobiome studies of other respiratory diseases have evolved rapidly. For instance, a
study on asthma patients showed higher fungal burdens in participants receiving corticoste-
roid therapy [7], while another study has revealed associations between Aspergillus-specific
immunisation and bronchiectasis severity [8]. There is clearly a need for large studies of the
mycobiome, with a well-characterised COPD disease population and healthy controls.
The Bergen COPD Microbiome study (short name “MicroCOPD”) fills this scientific void
[9]. Samples were collected from the lower airways of participants with and without COPD
using bronchoscopy. The aim of the current paper was threefold: 1) To characterise and com-
pare the oral and pulmonary mycobiomes in a large cohort of participants without lung disease
(controls). 2) To characterise the oral and pulmonary mycobiomes of participants with COPD,
and contrast it to controls, and finally, 3) To examine whether the mycobiomes were affected
by the use of inhaled steroids (ICS) in participants with COPD.
Materials and methods
Study design and population
The study design of the MicroCOPD study has previously been published [9]. MicroCOPD
was a single-centre observational study carried out in Bergen, Western Norway. Study enrol-
ment was between April 11th, 2013, and June 5th, 2015. The study was conducted in accordance
with the declaration of Helsinki and guidelines for good clinical practice. The regional com-
mittee of medical ethics Norway north division (REK-NORD) approved the project (project
number 2011/1307), and all participants provided written consent.
Both subjects with and without COPD were invited to participate. Participants from two
previous cohort studies in our vicinity, the GeneCOPD study and the Bergen COPD cohort
study, were contacted regarding participation in the current study, and some participants were
recruited through media, the local outpatient clinic, or among hospital staff [9]. Potential par-
ticipants were excluded if they had increased bleeding risk, unstable cardiac conditions, hyper-
capnia, or hypoxaemia when receiving oxygen supplement, as specified in the study protocol
[9]. We postponed participation for subjects that had used antibiotics or systemic steroids last
2 weeks prior to participation, and COPD patients should not have been admitted to hospital
due to COPD last 2 weeks. Furthermore, participants with symptoms of an ongoing systemic
or respiratory infection could not attend, but had to postpone participation. COPD was
defined as chronic airway obstruction (low FEV1/FVC) in presence of respiratory symptoms
[10], and the diagnosis was verified by experienced pulmonologists based on spirometry,
radiologic imaging, respiratory symptoms, and disease history. Subjects without COPD or
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other lung diseases were defined as control subjects. 22 control subjects had a ratio of FEV1/
FVC lower than 0.7, but did not have symptoms of COPD.
Data collection
All data collection was performed in our outpatient clinic. A post-bronchodilator spirometry
was performed before the bronchoscopy. Study personnel conducted a structured interview
regarding contraindications, medication use, comorbidities, smoking habits, and evaluation of
dyspnoea. A sterile unsealed bottle of phosphate-buffered saline (PBS) was opened prior to the
procedure, and the fluid within was used for all sample fluids, including negative control sam-
ples, oral wash (OW), and bronchoalveolar lavage (BAL). The OW sample was taken before
the bronchoscopy by gargling 10 ml of the PBS water for 1 minute; collected in a sterile Eppen-
dorf tube. The bronchoscopy was performed with the participant in supine position using oral
access. Topical anaesthesia was given by a 10 mg/dose lidocaine oral spray pre-procedurally,
and 20 mg/ml lidocaine was delivered per-operatively through a catheter within the broncho-
scope’s working channel. Light sedation with alfentanil was offered to all. The details of bron-
choscopic sampling have been published previously [9]. The yields of two fractions of
protected BAL of 50 mL were collected from the right middle lobe using a sterile catheter
(Plastimed Combicath, prod number 58229.19) inserted in the bronchoscope working chan-
nel. The second fraction was used for the current mycobiome analysis. Additionally, a sample
from the PBS was taken for each participant directly from the bottle used for that particular
participant, without entering the bronchoscope or participant. This PBS sample served as a
negative control sample.
Laboratory processing
Fungal DNA was extracted using a combination of enzymatic lysis with lysozyme, mutanoly-
sin, and lysostaphin, and mechanical lysis methods using the FastPrep-24 as described by the
manufacturers of the FastDNA Spin Kit (MP Biomedicals, LLC, Solon, OH, USA). Libraries
were prepared with a modified version of the Illumina 16S Metagenomic Sequencing Library
Preparation guide (Part no. 15044223 Rev. B). The internal transcribed spacer (ITS) 1 region
was PCR amplified (increased from 25 to 28 cycles) using primer set ITS1-30F/ITS1-217R,
which sequences are GTCCCTGCCCTTTGTACACA and TTTCGCTGCGTTCTTCATCG [11]. A
subsequent index PCR was performed with 9 cycles instead of 8. Samples underwent 2x250
cycles of paired-end sequencing in three separate sequencing runs on Illumina HiSeq (Illu-
mina Inc., San Diego, CA, USA).
Bioinformatics
Quantitative Insights into Microbial Ecology (QIIME) 2 [12] version 2019.01 and 2019.10 was
chosen as the main pipeline for bioinformatic analyses, and additional R packages were utilised
as suited [13]. FASTQ files containing all fungal reads were trimmed using the q2-itsxpress
plugin [14]. Trimmed reads were then denoised, i.e., identification and removal of low-quality
reads and chimeric sequences, using the Divisive Amplicon Denoising Algorithm version 2
(DADA2) q2-dada2 plugin [15]. DADA2 also generated exact amplicon sequence variants
(ASVs). LULU, an R package to curate DNA amplicon data post clustering, was used to
exclude artefactual ASVs [16]. ASVs present in only one sample, and ASVs with a total abun-
dance less than 10 sequences across all samples, were filtered out. Presumed contaminants
were identified using the R package Decontam [17] with the prevalence-based approach (user
defined threshold = 0.5), and then removed. Taxonomic assignments were made using a
UNITE database for fungi with clustering at 99% threshold level [18] (via q2-feature-classifier
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[19] classify-sklearn [20]). Resulting ASVs assigned only as Fungi at kingdom level, or Fungi at
kingdom level with unidentified phylum, were manually investigated using the BLASTN pro-
gram in NCBI [21]. ASVs with unambiguous BLASTN results with a high max score were
repeatedly assigned to new taxonomic assignments using UNITE databases with fungi or all
eukaryotes with different threshold levels [18, 22–24] (via q2-feature-classifier [19] classify-
sklearn [20] and classify-consensus-blast [25]), and included for further analyses if the new
assignments matched the BLASTN result. ASVs with ambiguous or non-fungal BLASTN
results were discarded. Alpha diversity was calculated using Shannon index, and beta diversity
metrics (Bray-Curtis dissimilarity and Jaccard similarity coefficient) were estimated using
q2-diversity after samples were rarefied (subsampled without replacement) to 1000 sequences
per sample. The rarefaction depth was chosen based on testing with multiple different values
and resulting alpha rarefaction plots. We aimed to find a rarefaction depth as high as possible
while excluding a minimum of samples.
Data analyses
Statistical analyses of demographical data were analysed with Stata version 15 [26]. A flow
chart of the bioinformatic process was generated using Flowchart Designer version 3 (http://
flowchart.lofter.com). Alpha- and beta diversity analyses including participants with COPD
were stratified by GOLD stage [10]. Statistical differences in alpha diversity measured with
Shannon index were tested with R using Kruskal-Wallis for unpaired variables, and Wilcoxon
signed-rank test for paired analyses. Differences in beta diversity between study groups and
ICS use were tested with permuted analysis of variance (PERMANOVA) adjusted for sex, age,
and percentage of predicted forced expiratory volume in 1 second (FEV1), and differences in
spread with permuted multivariate analysis of beta-dispersion (PERMDISP). Procrustes analy-
ses were performed to check for differences in beta diversity between sample types. PERMA-
NOVA, PERMDISP, and Procrustes were analysed using the Vegan package in R [27]. We
used both Bray-Curtis and Jaccard distances for the beta diversity analyses. To compare taxo-
nomic composition between pairs of samples we calculated the Yue-Clayton measure of dis-
similarity (1-θYC) [28]. Furthermore, differences in distributions and relative abundances
were evaluated by the Microbiome Differential Distribution Analysis (MicrobiomeDDA)
omnibus test [29], the second version of analysis of composition of microbiomes (ANCOM
v2, https://github.com/FrederickHuangLin/ANCOM) [30], and the second version of ANO-
VA-Like Differential Expression (ALDEx2) [31–33] at genus level. A significance level of 0.05
was used in all analyses.
Results
Demographics of participants
The majority of participants with COPD was regular ICS users, and presented with more
comorbidities, higher medication use, and poorer lung function measurements (FEV1/FVC-
ratio and mMRC) than controls (Table 1).
Flow chart. The bioinformatic processing is shown in Fig 1, and details are given in S1
File. ASVs identified by Decontam as presumed contaminants are listed in S1 Table.
Taxonomy and abundance/distribution testing. The taxonomic composition of the OW
and BAL mycobiomes are displayed on group level in the rank abundance plots (Fig 2A and
2B). Both controls and participants with COPD were dominated by Candida, particularly in
the OW samples, reaching nearly 80% of total mean relative abundance. The relative abun-
dances of Malassezia and Sarocladium were high in the control and COPD groups. We also
plotted percentage of reads belonging to either Basidiomycota or Ascomycota (S1 Fig). There
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seemed to be a tendency towards higher proportions of Basidiomycota in the COPD group
compared to the control group both in the OW and BAL plot. No consistent differences were
found between study groups in terms of differential abundance/distribution, and results varied
between available statistical tests (S2 Table).
Taxonomy is displayed for each individual participant in Fig 3A and 3B, enabling us to
compare OW and BAL samples from this particular participant. We observed intra-individual
differences between the sample types for the plotted taxonomic levels (phylum and genus).
This was elaborated with Yue-Clayton testing for each OW/BAL/negative control sample pair
(S2 Fig). The Yue-Clayton measure is 0 with perfect similarity and 1 with perfect dissimilarity.
The average Yue-Clayton measure from OW and BAL samples was 0.63, and 121 out of 180
sample pairs had a Yue-Clayton measure above 0.2. ANCOM and ALDEx2 (S2 Table) found
Candida to differ in abundance between OW and BAL, also stratified by smoking status and
ICS usage. The taxonomy of regular ICS users and non-ICS users was not easily distinguish-
able (Fig 3A and 3B), and no consistent differences were seen in differential abundance/distri-
bution testing (S3 Table).
Diversity
We found no significant differences in alpha diversities between the different study groups or
ICS usage in BAL samples, nor between BAL and OW samples (Fig 4A and 4B, S3 Table).
Beta-diversity results resembled those of alpha diversity (S3 Fig). However, principal coordi-
nates analysis (PCoA) plots before and after symmetric Procrustes transformation (S4 Fig),
indicated that there were significant differences in the composition between OW and BAL
samples from the same individual. The Procrustes transformation yields a sum of squared dis-
tances (M^2) that specifies how similar sample pairs are. Generally, a M^2 above 0.3 is
Table 1. Demographics of participants providing fungal samples in the MicroCOPD study.
Variable Control, n = 100 COPD, n = 93
Age, mean years (SD) 65.6 (8.5) 67.5 (7.6)
Male, sex (%) 57 (57.0) 50 (53.8)
Number of medications, mean (SD) 1.8 (1.7) 5.2 (3.1)
Use of inhaled steroids (%) - 56 (60.2)
Number of comorbidities, mean (SD) 0.8 (1.0) 1.4 (1.2)
FEV1, mean % of predicted (SD) 104.0 (12.3) 61.1 (17.3)
FVC, mean % of predicted (SD) 111.7 (13.6) 98.6 (18.7)
FEV1/FVC-ratio, mean (SD) 0.7 (0.1) 0.5 (0.1)
Pack years, mean (SD) 16.6 (14.3) 30.0 (17.9)
Smoking status (%)
Daily 24 (24.0) 22 (23.7)
Ex-smokers 58 (58.0) 70 (75.3)
Never 18 (18.0) 1 (1.1)
mMRC Grade 2 and higher (%)�
Grade 2: Dyspnoea when walking at level ground 3 (3.0) 16 (17.6)
Grade 3: Dyspnoea when walking 100 meters - 12 (13.2)
Grade 4: Dyspnoea at rest - 2 (2.2)
FEV1: forced expiratory volume in 1 second, FVC: forced vital capacity, mMRC: modified medical research council
dyspnoea scale.
� Two participants with COPD missed information on mMRC.
https://doi.org/10.1371/journal.pone.0248967.t001
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Fig 1. Flow chart of fungal samples, sequences, and fungal ASVs in the MicroCOPD study. DADA2: Divisive
Amplicon Denoising Algorithm version 2, seqs: sequences, ASV: amplicon sequence variant. Samples were sequenced
in three different runs before trimming and denoising. Data from different sequencing runs were merged, and then
further processed to exclude presumed contaminants and negative control samples prior to analyses.
https://doi.org/10.1371/journal.pone.0248967.g001
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interpreted as unsimilar. OW and BAL samples clustered differently, and M^2 were 0.953 and
0.8958 for Bray-Curtis and Jaccard, respectively. However, this was statistically significant only
for Jaccard (p = 0.003).
Fig 2. Rank abundance plots using most abundant fungi in (A) oral wash and (B) bronchoalveolar lavage. Plots
display the nine most abundant taxa in each group. Remaining, low abundance taxa are merged in the “Others”
category. Not all sequences could be assigned taxonomy at the genus level and are therefore displayed as
o__Malasseziales, p__Ascomycota, and o__Capnodiales.
https://doi.org/10.1371/journal.pone.0248967.g002
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Discussion
We have reported the oral and pulmonary mycobiome in a large bronchoscopy study, the first
of its kind on non-immunocompromised patients and with a large healthy control population.
The mycobiomes were dominated by Candida, and there were more Candida in OW com-
pared to BAL for both study groups. Observed differences in taxonomic composition were not
consistent between three different differential abundance/distribution tests. There was no dif-
ference in diversity between study groups. No apparent effects were seen on the mycobiomes
from ICS usage.
Fig 3. Most abundant fungal taxonomic assignments at (A) phylum level and (B) genus level. ICS: inhaled steroids,
BAL: bronchoalveolar lavage, OW: oral wash. Taxa are sorted on Ascomycota in bronchoalveolar lavage samples in Fig
3A, and Candida in bronchoalveolar lavage in Fig 3B. Each column represents a sample, and columns from BAL and
OW corresponds to each other. That means, a BAL column and the corresponding OW column below show samples
from the same participant. Not all sequences could be assigned taxonomy at the phylum or genus level and are
therefore displayed as k__Fungi, p__Ascomycota or o__Malasseziales.
https://doi.org/10.1371/journal.pone.0248967.g003
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Fig 4. Alpha diversity plots and comparisons between (A) study groups and (B) sample types. BAL: bronchoalveolar
lavage, OW: oral wash. Alpha diversity was evaluated using Shannon index. Statistical differences in alpha diversity
were tested using Kruskal-Wallis for unpaired variables (between study groups), and Wilcoxon signed-rank test for
paired analyses (between sample types). Number of samples in each group was as follows: Fig 4A (unpaired): Control
BAL: 40, control OW: 76, COPD grade I/II BAL: 29, COPD grade I/II OW: 50, COPD grade III/IV OW: 23, COPD
grade III/IV BAL: 12. Fig 4B (paired): Control BAL: 31, control OW: 31, COPD grade I/II BAL: 24, COPD grade I/II
OW: 24, COPD grade III/IV OW: 9, COPD grade III/IV BAL: 9.
https://doi.org/10.1371/journal.pone.0248967.g004
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We observed a high Candida load in OW samples from controls, in good agreement with
previously published studies [34–36]. None of these studies included more than 20 individuals.
Thus, our data from 100 controls adds valuable data to this field. The healthy lung mycobiome
is reported to be highly variable between individuals [4, 6, 7, 37–39]. Some of the most abun-
dant taxa are Candida [6], Davidiellaceae [37], Cladosporium [37–39], Saccharomyces [4, 6],
Penicillium [4], Debaryomyces [38], Aspergillus [7, 37], Eremothecium [39], Systenostrema [39],
and Malasseziales [7]. The listed studies include few participants, ranging from 10 [7] to 47 [6].
BAL samples from controls in the current study were dominated by Candida, followed by
Malassezia and Sarocladium. That Candida, one of the most well-known fungal pathogens
[40], resides in the lungs of healthy individuals is clinically interesting. It has been shown that
colonising Candida in the gut could become invasive due to certain triggers [41], and similar
mechanisms are not unlikely to happen in the lungs. Primer bias might explain some of the
observed differences between our study and previous studies [42], and our chosen primer set
has shown improved coverage of Candida compared to the ITS1 –ITS2 primer set used by two
[37, 38] of the listed papers above [11]. Furthermore, Malassezia are common skin commen-
sals, and despite protected sampling and the bioinformatic contamination removal (Decon-
tam), we cannot exclude contamination per se. Also, some reports indicate that some
extraction protocols and primers might be less suited to Malassezia [36, 43]. Different DNA
extraction methods and primers could thus explain the observed differences in Malassezia pro-
portions between our study and others.
OW samples differed from the BAL samples for all measures including taxonomy, Yue-
Clayton measures, and beta diversity. Cui et al. reported that OW and BAL overlapped in
PCoA plots from healthy individuals, while induced sputum (IS) samples clustered separately
[4]. In agreement with our result, they also found more Candida in OW and IS, compared to
BAL. They discovered that 39 fungal species were disproportionately more abundant in the
BAL and 203 species in the IS, as compared with the OW. We could not replicate this latter
finding, but differences could be explained by the different methodologies applied.
Only three previous studies have explored the lung mycobiome in COPD [4–6]. Cui et al.
found that the lung mycobiome in HIV-infected individuals with COPD (n = 10) was associ-
ated with an increased prevalence of Pneumocystis jirovecii, as compared to HIV-positive indi-
viduals without COPD (n = 22) [4]. No Pneumocystis was observed in our data. However,
Pneumocystis is known to be associated with HIV, and the Pneumocystis genome only includes
one copy of the ITS1 locus, which could result in a negative sequencing result [44].
Both Su et al. [5] and Tiew et al. [6] collected sputum samples from COPD patients. When
Tiew compared to healthy subjects they found high abundances of Candida in both groups,
but also found increased alpha diversity in COPD [6]. Su investigated samples during exacer-
bations, and found Candida, Phialosimplex, Aspergillus, Penicillium, Cladosporium, and Euty-
pella [5]. Both studies utilised sputum samples, which hampers direct comparison to our BAL
samples. Indeed, IS samples have been shown to cluster separately from BAL samples in PCoA
ordinations [4].
Few differences were seen when we compared the mycobiomes from controls and partici-
pants with COPD. However, hypothesis testing of microbiome compositional data is an ongo-
ing research area without standardisation. Thus, we chose to perform three different tests with
different foundations. ANCOM v2 and ALDEx2 agreed there was no significantly differential
abundant taxa between study groups. MicrobiomeDDA tests the difference in the entire distri-
bution, taking abundance, prevalence, and dispersion all into account, and detected significant
taxa differences between study groups both in OW and BAL (S2 Table). These conflicting
results complicate a general conclusion.
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Some studies on inflammatory bowel disease, and cystic fibrosis (CF) have found dysbiosis
to be expressed in terms of the Basidiomycota to Ascomycota ratio [45, 46]. Most known fungal
pathogens are found in the Ascomycota phylum. In our study, medians of the Basidiomycota to
Ascomycota ratios were all 0 from different study groups in OW and BAL separately, in line
with the 0.03 median found in a CF study [46]. That means, despite a higher Basidiomycota
fraction in COPD compared to controls in our data (S1 Fig), the majority of samples were
dominated by Ascomycota.
Some limitations of the current study deserve mentioning. First, a longitudinal study with
analyses on interactions between fungi and other kingdoms, and between fungi and host
responses, could have provided more insight into the details of the COPD mycobiome. Sec-
ondly, contamination is particularly problematic for mycobiome studies because of airborne
particles, and samples from the lower respiratory tract are especially vulnerable due to the low
biomass. We countered this by using protected sampling methods, and collecting negative
control samples, subject to the same laboratory protocol as the procedural samples, for each
procedure. These samples were used for contamination removal through the R package
Decontam, and subject to detailed analyses (S2 Fig, S4 Table and S5 Fig). Third, we did not
include positive controls or mock communities in our project. Fourth, ITS primers are biased
[42, 43], possibly explaining the low prevalence of Aspergillus and difficulties identifying Yar-
rowia lypolytica in our data. Still, ITS is the recommended marker-gene region for fungal stud-
ies [47], though no consensus seems to prevail whether ITS1 or ITS2 should be used [43, 48,
49]. Fifth, all mycobiome studies suffer from a fungal dual naming system [50], and also suffer
from incomplete reference libraries and inconsistencies due to taxonomic reassignments [2].
We manually reviewed every sequence assigned only as “k__Fungi” to secure the best possible
taxonomy. Finally, confounding factors and batch effects could not be ruled out. We included
a thorough examination of diversity and differential abundance/distribution testing to look for
potential confounding effects from several important clinical parameters (S3 Table). No appar-
ent effects were seen. We observed no statistically significant difference in alpha diversity
between sequencing runs (S5 Fig), but there might have been an effect on beta diversity (S6
Fig), particularly between sequencing run 1 and 2 (S5 Table). In terms of differential abun-
dance/distribution, it seemed that Sarocladium differed in abundance/distribution between
sequencing run 1 and 2 (S7 Table).
Studies on the lung mycobiome are still in their infancy, and results from the current study
add knowledge to an understudied area. Samples from the mouth differed from pulmonary
samples both in controls and participants with COPD, which may indicate the existence of a
pulmonary mycobiome. Certain inferences on taxonomic compositions differences between
study groups could not be made due to inconsistent results among the differential abundance/
distribution tests used. ICS use could not be seen to significantly affect the lung mycobiome.
These findings should be confirmed in other study populations before we can conclude that
ICS use has no harmful effect on the lung mycobiome.
Supporting information
S1 Fig. Percentage of reads belonging to Ascomycota/Basidiomycota in (A) oral wash and (B)
bronchoalveolar lavage.
(PDF)
S2 Fig. Yue-Clayton measures from (A) controls and (B) participants with COPD. YC: Yue-
Clayton measure. OW: oral wash, NCS: negative control sample, BAL: bronchoalveolar lavage.
A Yue-Clayton measure of 0 means identical sample pairs, while a Yue-Clayton measure of 1
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means unidentical sample pairs.
(PDF)
S3 Fig. Principal coordinates analysis plots by (A) study group and (B) inhaled steroids use.
Differences in beta diversity were tested with permuted analysis of variance (PERMANOVA)
adjusted for sex, age, and percentage of predicted FEV1 (permutations = 10000). No signifi-
cant differences were seen in spread/dispersion (permutations = 1000).
(PDF)
S4 Fig. Principal coordinates analysis plots by sample type (A) before and (B) after symmetric
Procrustes transformation. OW: oral wash, BAL: bronchoalveolar lavage. Arrows are drawn
from the OW sample to the BAL sample from the same participant. Non-randomness (“signif-
icance”) between the two configurations was tested with the protest function including the
three first axis from the PCoA and specifying 999 permutations.
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S5 Fig. Plot of Qubit concentrations and comparisons between sample types. BAL: bronch-
oalveolar lavage, NCS: negative control sample, OW: oral wash. Statistical differences in Qubit
concentrations were tested using Wilcoxon signed-rank test as a paired test.
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S6 Fig. Alpha diversity plots and comparisons between sequencing runs. BAL: bronchoal-
veolar lavage, OW: oral wash. Alpha diversity was evaluated using Shannon index. Statistical
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S1 Table. Presumed fungal contaminants identified by Decontam in the MicroCOPD
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S2 Table. Differential abundance/distribution testing on fungi in the MicroCOPD study
using ANCOM v2, MicrobiomeDDA, and ALDEx2. ANCOM v2: the second version of anal-
ysis of composition of microbiomes, MicrobiomeDDA: Microbiome Differential Distribution
Analysis omnibus test, ALDEx2: the second version of ANOVA-Like Differential Expression,
OW: oral wash, BAL: bronchoalveolar lavage. The most conservative value in ANCOM v2 has
been used in the analyses (i.e. 0.9). Significance level = 0.05. Never- and ex-smokers were
merged into non-smokers. The ALDEx2 approach works poorly if there are only a small num-
ber of taxa (less than about 50), so some groups were not analysed.
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S3 Table. Taxonomy and diversity comparisons of selected clinical variables in the Micro-
COPD study divided by sample type and study group. PERMANOVA: permuted analysis of
variance, OW: oral wash, BAL: bronchoalveolar lavage, AN: ANCOM v2, M: Microbio-
meDDA, AL: ALDEx2, sign: significant, FEV1: forced expiratory volume in 1 second. Analyses
on FEV1 were omitted for each study group separately due to a majority of controls having
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tion of microbiomes, MicrobiomeDDA: Microbiome Differential Distribution Analysis omni-
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